The immune system of the gut and potential adverse effects of oral nanocarriers on its function

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 402-409

  Őrfi, Erik ^a   Szebeni, János ^a,b  

^a SeroScience Ltd   (Hungary)

^b UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

Gut microbiome; Intestinal permeation enhancers; Oral nanotechnology; Oral peptides; Peptide clinical trials; Therapeutic peptides

Indexed keywords

DRUG PRODUCTS; PEPTIDES; TISSUE; TOXICITY; VACCINES; VIRUSES;

CLINICAL TRIAL; COMPLEMENT ACTIVATIONS; DRUG DELIVERY SYSTEM; HUMORAL IMMUNE RESPONSE; INTESTINAL PERMEATIONS; MICROBIOME; MUCOSA-ASSOCIATED LYMPHOID TISSUE; THERAPEUTIC PEPTIDES;

IMMUNE SYSTEM;

COMPLEMENT; CREMOPHOR; DOCETAXEL; DOCUSATE SODIUM; DOXORUBICIN; EMULSIFYING AGENT; IMMUNOGLOBULIN A; NANOCARRIER; NANOPARTICLE; NANOSILICA PARTICLE; PACLITAXEL; POLIOMYELITIS VACCINE; POLYSORBATE 80; ROSMARINIC ACID; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER;

ALLERGIC REACTION; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; EPITHELIUM CELL; HISTAMINE BLOOD LEVEL; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INTESTINE; INTESTINE LYMPHATIC TISSUE; LYMPH FOLLICLE; LYMPHOCYTE; MICELLE; MICROFOLD CELL; MUCOSA ASSOCIATED LYMPHOID TISSUE; MUCOSAL IMMUNITY; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TISSUE STRUCTURE; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; INTESTINE MUCOSA; PATHOLOGY;

ANIMALS; COMPLEMENT ACTIVATION; DRUG CARRIERS; EMULSIFYING AGENTS; HUMANS; IMMUNE SYSTEM; INTESTINAL MUCOSA; MICELLES;

EID: 84996528914     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.09.009     Document Type: Review

References (81)

1. [1] Skinner, J.M., Whitehead, R., Morphological methods in the study of the gut immune system in man. J. Clin. Pathol. 29 (1976), 564–567.
2. [2] Husband, A.J., Ontogeny of the gut-associated immune system. Adv. Exp. Med. Biol. 137 (1981), 633–647.
3. [3] Schmiegel, W.H., Thiele, H.G., Immunoregulation by the gut-associated immune system. Immun. Infekt. 10 (1982), 169–174.
4. [4] Woloschak, G.E., Tomasi, T.B., The immunology and molecular biology of the gut-associated immune system. Crit. Rev. Immunol. 4 (1983), 1–18.
5. [5] Borsch, G., The gastrointestinal tract as an immunologic organ: the gut-associated immune system. Klin. Wochenschr. 62 (1984), 699–709.
6. [6] Nagura, H., Sumi, Y., Immunological functions of the gut—role of the mucosal immune system. Toxicol. Pathol. 16 (1988), 154–164.
7. [7] Castro, G.A., Arntzen, C.J., Immunophysiology of the gut: a research frontier for integrative studies of the common mucosal immune system. Am. J. Phys. 265 (1993), G599–G610.
8. [8] Bland, P.W., Gut epithelium: food processor for the mucosal immune system?. Gut 42 (1998), 455–456.
9. [9] Cunningham-Rundles, S., Lin, D.H., Nutrition and the immune system of the gut. Nutrition 14 (1998), 573–579.
10. [10] Pabst, R., Rothkotter, H.J., Structure and function of the gut mucosal immune system. Adv. Exp. Med. Biol. 579 (2006), 1–14.
11. [11] Battersby, A.J., Gibbons, D.L., The gut mucosal immune system in the neonatal period. Pediatr. Allergy Immunol. 24 (2013), 414–421.
12. [12] Castro-Sanchez, P., Martin-Villa, J.M., Gut immune system and oral tolerance. Br. J. Nutr. 109:Suppl. 2 (2013), S3–S11.
13. [13] Magrone, T., Jirillo, E., The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun. Ageing, 10, 2013, 31.
14. [14] Magrone, T., Jirillo, E., The interplay between the gut immune system and microbiota in health and disease: nutraceutical intervention for restoring intestinal homeostasis. Curr. Pharm. Des. 19 (2013), 1329–1342.
15. [15] Croitoru, K., Bienenstock, J., Ernst, P.B., Phenotypic and functional assessment of intraepithelial lymphocytes bearing a ‘forbidden’ alpha beta TCR. Int. Immunol. 6 (1994), 1467–1473.
16. [16] Hiroi, T., Iwatani, K., Iijima, H., Kodama, S., Yanagita, M., Kiyono, H., Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur. J. Immunol. 28 (1998), 3346–3353.
17. [17] Kiyono, H., Fukuyama, S., NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4 (2004), 699–710.
18. [18] Yamamoto, M., Kweon, M.N., Rennert, P.D., Hiroi, T., Fujihashi, K., McGhee, J.R., Kiyono, H., Role of gut-associated lymphoreticular tissues in antigen-specific intestinal IgA immunity. J. Immunol. 173 (2004), 762–769.
19. [19] Shikina, T., Hiroi, T., Iwatani, K., Jang, M.H., Fukuyama, S., Tamura, M., Kubo, T., Ishikawa, H., Kiyono, H., IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J. Immunol. 172 (2004), 6259–6264.
20. [20] Giuliano, E.A., Moore, C.P., Phillips, T.E., Morphological evidence of M cells in healthy canine conjunctiva-associated lymphoid tissue. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 240 (2002), 220–226.
21. [21] Astley, R.A., Kennedy, R.C., Chodosh, J., Structural and cellular architecture of conjunctival lymphoid follicles in the baboon (Papio anubis). Exp. Eye Res. 76 (2003), 685–694.
22. [22] Conley, M.E., Delacroix, D.L., Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?. Ann. Intern. Med. 106 (1987), 892–899.
23. [23] Ogra, P.L., Faden, H., Welliver, R.C., Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14 (2001), 430–445.
24. [24] Macdonald, T.T., Monteleone, G., Immunity, inflammation, and allergy in the gut. Science 307 (2005), 1920–1925.
25. [25] Mabbott, N.A., Donaldson, D.S., Ohno, H., Williams, I.R., Mahajan, A., Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 6 (2013), 666–677.
26. [26] Kelsall, B.L., Strober, W., Peyer's patch dendritic cells and the induction of mucosal immune responses. Res. Immunol. 148 (1997), 490–498.
27. [27] Mantis, N.J., Rol, N., Corthesy, B., Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4 (2011), 603–611.
28. [28] Yeh, H.Z., Chen, G.H., Chang, W.D., Poon, S.K., Yang, S.S., Lien, H.C., Chang, C.S., Chou, G., Long-term follow up of gastric low-grade mucosa-associated lymphoid tissue lymphoma by endosonography emphasizing the application of a miniature ultrasound probe. J. Gastroenterol. Hepatol. 18 (2003), 162–167.
29. [29] Mantis, N.J., Rediscovering IgA. Mucosal Immunol. 4 (2011), 588–589.
30. [30] Pabst, R., The anatomical basis for the immune function of the gut. Anat. Embryol. 176 (1987), 135–144.
31. [31] Pabst, O., Ohl, L., Wendland, M., Wurbel, M.A., Kremmer, E., Malissen, B., Forster, R., Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J. Exp. Med. 199 (2004), 411–416.
32. [32] Eberl, G., Littman, D.R., Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat + cells. Science 305 (2004), 248–251.
33. [33] Kelsall, B.L., Strober, W., Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J. Exp. Med. 183 (1996), 237–247.
34. [34] Oida, T., Suzuki, K., Nanno, M., Kanamori, Y., Saito, H., Kubota, E., Kato, S., Itoh, M., Kaminogawa, S., Ishikawa, H., Role of gut cryptopatches in early extrathymic maturation of intestinal intraepithelial T cells. J. Immunol. 164 (2000), 3616–3626.
35. [35] Parashar, A., Udayabanu, M., Gut microbiota regulates key modulators of social behavior. Eur. Neuropsychopharmacol. 26 (2016), 78–91.
36. [36] Quigley, E.M., Gut bacteria in health and disease. Gastroenterol. Hepatol. 9 (2013), 560–569.
37. [37] Quigley, E.M., Shanahan, F., The future of probiotics for disorders of the brain-gut axis. Adv. Exp. Med. Biol. 817 (2014), 417–432.
38. [38] Tellez, G., Prokaryotes Versus Eukaryotes: Who is Hosting Whom?. Front. Vet. Sci., 1, 2014, 3.
39. [39] Blottiere, H.M., de Vos, W.M., Ehrlich, S.D., Dore, J., Human intestinal metagenomics: state of the art and future. Curr. Opin. Microbiol. 16 (2013), 232–239.
40. [40] Shanahan, F., Gut flora in gastrointestinal disease. Eur. J. Surg. Suppl., 2002, 47–52.
41. [41] Bocci, V., The neglected organ: bacterial flora has a crucial immunostimulatory role. Perspect. Biol. Med. 35 (1992), 251–260.
42. [42] Knight, D.J., Girling, K.J., Gut flora in health and disease. Lancet, 361, 2003, 1831.
43. [43] Guarner, F., Malagelada, J.R., Gut flora in health and disease. Lancet 361 (2003), 512–519.
44. [44] Dinan, T.G., Cryan, J.F., Mood by microbe: towards clinical translation. Genome Med., 8, 2016, 36.
45. [45] Girardin, S.E., Hugot, J.P., Sansonetti, P.J., Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24 (2003), 652–658.
46. [46] Plummer, E.M., Manchester, M., Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3 (2011), 174–196.
47. [47] Szebeni, J., Barenholz, Y., Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes. Peer, D., (eds.) Handbook of Harnessing Biomaterials in Nanomedicine: Prepara!on,Toxicity, and Applications, 2012, Pan Standford Publishing Pte. Ltd., Singapure, 309–334.
48. [48] Patel, B.D., Modi, R.V., Thakkar, N.A., Patel, A.A., Thakkar, P.H., Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene. J. Pharm. Bioallied Sci. 4 (2012), S14–S16.
49. [49] WHO, Polio vaccines: WHO position paper. Wkly Epidemiol. Rec. 89 (2014), 73–92.
50. [50] Alving, C.R., Beck, Z., Matyas, G.R., Rao, M., Liposomal adjuvants for human vaccines. Expert Opin. Drug Deliv. 13 (2016), 807–816.
51. [51] Matyas, G.R., Mayorov, A.V., Rice, K.C., Jacobson, A.E., Cheng, K., Iyer, M.R., Li, F., Beck, Z., Janda, K.D., Alving, C.R., Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 31 (2013), 2804–2810.
52. [52] Zollinger, W.D., Babcock, J.G., Moran, E.E., Brandt, B.L., Matyas, G.R., Wassef, N.M., Alving, C.R., Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. Vaccine 30 (2012), 712–721.
53. [53] Alving, C.R., Rao, M., Steers, N.J., Matyas, G.R., Mayorov, A.V., Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev. Vaccines 11 (2012), 733–744.
54. [54] Richards, R.L., Alving, C.R., Wassef, N.M., Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. J. Pharm. Sci. 85 (1996), 1286–1289.
55. [55] Alving, C.R., Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann. N. Y. Acad. Sci. 754 (1995), 143–152.
56. [56] Wassef, N.M., Alving, C.R., Richards, R.L., Liposomes as carriers for vaccines. ImmunoMethods 4 (1994), 217–222.
57. [57] Merisko-Liversidge, E., Liversidge, G.G., Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63 (2011), 427–440.
58. [58] Lorenz, W., Riemann, H.J., Schmal, A., Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 7 (1977), 63–67.
59. [59] Szebeni, J., Muggia, F.M., Alving, C.R., Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90 (1998), 300–306.
60. [60] Ennis, M., Lorenz, W., Modulation of histamine release by fatty acids. A new in vitro model investigating adverse drug reactions in various species. Ann. Fr. Anesth. Reanim. 4 (1985), 124–128.
61. [61] Gaudy, J.H., Sicard, J.F., Lhoste, F., Boitier, J.F., The effects of cremophor EL in the anaesthetized dog. Can. J. Anaesth. 34 (1987), 122–129.
62. [62] Szebeni, J., Alving, C.R., Rosivall, L., Bünger, R., Baranyi, L., Bedöcs, P., Tóth, M., Barenholz, Y., Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 17 (2007), 107–117.
63. [63] Jackman, J.A., Meszaros, T., Fulop, T., Urbanics, R., Szebeni, J., Cho, N.J., Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model. Nanomedicine 12 (2016), 933–943.
64. [64] Moghimi, S.M., Wibroe, P.P., Szebeni, J., Hunter, A.C., Surfactant-mediated complement activation in beagle dogs. Int. Immunopharmacol. 17 (2013), 33–34.
65. [65] Qiu, S., Liu, Z., Hou, L., Li, Y., Wang, J., Wang, H., Du, W., Wang, W., Qin, Y., Liu, Z., Complement activation associated with polysorbate 80 in beagle dogs. Int. Immunopharmacol. 15 (2013), 144–149.
66. [66] Ennis, M., Lorenz, W., Kapp, B., Luben, L., Schmal, A., Comparison of the histamine-releasing activity of cremophor E1 and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. Agents Actions 16 (1985), 265–268.
67. [67] Colace, What Is Colace (Docusate Sodium)?. http://www.everydayhealth.com/drugs/colace, 2016.
68. [68] Szebeni, J., Muggia, F., Gabizon, A., Barenholz, Y., Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 63 (2011), 1020–1030.
69. [69] Szebeni, J., Muggia, F., Barenholz, Y., Case study: Complement activation related hypersensitivity reactions to PEGylated liposomal doxorubicin: Experimental and clinical evidence, mechanisms and approaches to Inhibition. Dobrovolskaia, M.A., McNeil, S.E., (eds.) Handbook of Immunological Properties of Engineered Nanomaterials, 2nd edition, 2015, World Scientific Publishing Company, 331–361.
70. [70] Moon, M.R., Parikh, A.A., Pritts, T.A., Fischer, J.E., Cottongim, S., Szabo, C., Salzman, A.L., Hasselgren, P.O., Complement component C3 production in IL-1beta-stimulated human intestinal epithelial cells is blocked by NF-kappaB inhibitors and by transfection with ser 32/36 mutant IkappaBalpha. J. Surg. Res. 82 (1999), 48–55.
71. [71] Andoh, A., Fujiyama, Y., Bamba, T., Hosoda, S., Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2. J. Immunol. 151 (1993), 4239–4247.
72. [72] Bergin, I.L., Witzmann, F.A., Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps, International journal of biomedical nanoscience and nanotechnology, 3. 2013.
73. [73] Madureira, A.R., Nunes, S., Campos, D.A., Fernandes, J.C., Marques, C., Zuzarte, M., Gullon, B., Rodriguez-Alcala, L.M., Calhau, C., Sarmento, B., Gomes, A.M., Pintado, M.M., Reis, F., Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. Int. J. Nanomedicine 11 (2016), 3621–3640.
74. [74] Madureira, A.R., Campos, D.A., Oliveira, A., Sarmento, B., Pintado, M.M., Gomes, A.M., Insights into the protective role of solid lipid nanoparticles on rosmarinic acid bioactivity during exposure to simulated gastrointestinal conditions. Colloids Surf. B Biointerfaces 139 (2016), 277–284.
75. [75] Pietroiusti, A., Magrini, A., Campagnolo, L., New frontiers in nanotoxicology: Gut microbiota/microbiome-mediated effects of engineered nanomaterials. Toxicol. Appl. Pharmacol. 299 (2016), 90–95.
76. [76] Toda, T., Yoshino, S., Amorphous nanosilica particles block induction of oral tolerance in mice. J. Immunotoxicol. 13 (2016), 723–728.
77. [77] Frohlich, E.E., Frohlich, E., Cytotoxicity of Nanoparticles Contained in Food on Intestinal Cells and the Gut Microbiota. Int. J. Mol. Sci., 17, 2016, 509.
78. [78] Sarkar, B., Jaisai, M., Mahanty, A., Panda, P., Sadique, M., Nayak, B.B., Gallardo, G., Thakur, D., Bhattacharjee, S., Dutta, J., Optimization of the sublethal dose of silver nanoparticle through evaluating its effect on intestinal physiology of Nile tilapia (Oreochromis niloticus L.). J. Environ. Sci. Health, Part A: Tox. Hazard. Subst. Environ. Eng. 50 (2015), 814–823.
79. [79] Williams, K., Milner, J., Boudreau, M.D., Gokulan, K., Cerniglia, C.E., Khare, S., Effects of subchronic exposure of silver nanoparticles on intestinal microbiota and gut-associated immune responses in the ileum of Sprague-Dawley rats. Nanotoxicology 9 (2015), 279–289.
80. [80] Merrifield, D.L., Shaw, B.J., Harper, G.M., Saoud, I.P., Davies, S.J., Handy, R.D., Henry, T.B., Ingestion of metal-nanoparticle contaminated food disrupts endogenous microbiota in zebrafish (Danio rerio). Environ. Pollut. 174 (2013), 157–163.
81. [81] Shumakova, A.A., Efimochkina, N.R., Minaeva, L.P., Bykova, I.B., Batishchava, S.Y., Markova, Y.M., Trushina, E.N., Mustafina, O.K., Sharanova, N.E., Gmoshinsky, I.V., Khanferyan, R.A., Khotimchenko, S.A., Sheveleva, S.A., Tutelyan, V.A., Toxicological assessment of nanostructured silica. III. Microecological, hematological indices, state of cellular immunity. Vopr. Pitan. 84 (2015), 55–65.